Background and Objective: In this mini-review, we have compiled the most recent and
comparable information to shed light on the action of PEGylation in the biodistribution of carbon
nanotubes (CNT) in the central nervous system (CNS). It is well known that due to the complexity of
the CNS and the severity of the outcome following changes in this system, this is one of the areas
where there are more investments in research to develop new technologies and approaches for more
effective and less invasive treatments. The CNS is highly protected against toxic and invasive microorganisms
thanks to the blood brain barrier (BBB), but this protection also prevents the passage of potentially
beneficial molecules for the treatment of neurological disorders. Nanotechnology attempts to
develop nanocompounds that are biocompatible and non-immunogenic, and that are able to cross the
BBB in therapeutic amounts without causing damage and to diffuse through nerve tissue. These compounds
should also be cleared and biodistributed properly, being capable of performing drug delivery
exclusively for CNS pathologies, such as neurodegenerative diseases (Parkinson's and Alzheimer's)
and brain tumors.
Conclusion: In this way, this review focuses on CNT PEGylation, aiming to help in the development
of viable and effective nanomedicines for neuroscience applications.